Geode Capital Management LLC Buys 14,015 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Geode Capital Management LLC increased its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.5% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 920,363 shares of the company’s stock after acquiring an additional 14,015 shares during the period. Geode Capital Management LLC’s holdings in Amphastar Pharmaceuticals were worth $44,674,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of AMPH. TD Asset Management Inc lifted its holdings in shares of Amphastar Pharmaceuticals by 67.4% during the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock valued at $67,663,000 after acquiring an additional 680,976 shares during the period. Epoch Investment Partners Inc. lifted its holdings in Amphastar Pharmaceuticals by 35.1% during the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock valued at $43,154,000 after purchasing an additional 280,390 shares during the last quarter. American Century Companies Inc. boosted its position in Amphastar Pharmaceuticals by 19.7% in the second quarter. American Century Companies Inc. now owns 740,408 shares of the company’s stock valued at $29,616,000 after buying an additional 121,764 shares in the last quarter. Millennium Management LLC grew its stake in Amphastar Pharmaceuticals by 84.6% during the second quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock worth $29,550,000 after buying an additional 338,653 shares during the last quarter. Finally, Boston Trust Walden Corp acquired a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth approximately $26,189,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on AMPH shares. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Wells Fargo & Company started coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 target price for the company. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $60.33.

Amphastar Pharmaceuticals Stock Performance

AMPH stock opened at $39.12 on Tuesday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $36.56 and a twelve month high of $65.92. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The company has a market cap of $1.88 billion, a P/E ratio of 13.04, a price-to-earnings-growth ratio of 0.87 and a beta of 0.78. The business’s fifty day moving average is $46.26 and its 200-day moving average is $44.56.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $48.80, for a total transaction of $244,000.00. Following the sale, the director now directly owns 31,471 shares in the company, valued at approximately $1,535,784.80. This trade represents a 13.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO William J. Peters sold 7,426 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $386,523.30. Following the completion of the transaction, the chief financial officer now owns 94,103 shares of the company’s stock, valued at $4,898,061.15. This trade represents a 7.31 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,533 shares of company stock valued at $1,987,482. 27.10% of the stock is currently owned by company insiders.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.